This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove Biopharma Remove Competition Remove Networking Remove Safety
article thumbnail

Drug repurposing, real world data and AI/ML: perspectives and opportunities

Clarivate

OCTOBER 19, 2023

Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects). This process allows to impute/predict missing links.

Networking 59
Networking Consulting Safety Side effects 59
article thumbnail

ESMO 2022: Ten key takeaways on Europe’s top oncology event

Clarivate

OCTOBER 10, 2022

Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. Fruquintinib was well-tolerated, with a safety profile consistent with that previously reported in other studies. Hutchmed´s fruquintinib is a highly selective and potent oral inhibitor of VEGFR1-3. months; HR: 0.321, P<0.001).

Marketing 52
Marketing Safety Patients Competition 52
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024